Ali Health's stock surged 5.19% during the intraday session, reflecting strong investor optimism following significant platform developments.

The movement is attributed to the company securing exclusive online first-launch rights for two major innovative drugs. Hengrui Medicine's Ruiming, China's first domestically developed high-selectivity URAT1 inhibitor for gout, and Yangtze River Pharmaceutical's Taitutuo, a next-generation PDE5 inhibitor, both launched exclusively on Ali Health's platform. This dual endorsement from leading pharmaceutical companies validates Ali Health's channel value and digital service capabilities in the commercialization of innovative drugs, reinforcing its strategic position as a premier launch platform for new specialty medications.

Management has previously identified innovative drug categories as a core growth driver, projecting revenue growth of 10% to 15% year-over-year for the fiscal year 2027. The platform's integrated B2C and O2O model continues to attract positive analyst coverage, with several investment banks maintaining Buy ratings on the stock.